Keywords: Hyperpolarized MR (Non-Gas), Cancer, Treatment Response Prediction, Radiotherapy, Brain Metastases, MetabolismBrain metastases are increasingly being treated with stereotactic radiosurgery; however, 20-30% of treated tumors locally recure post treatment. Hyperpolarized [1-13C]pyruvate magnetic resonance imaging (HP 13C MRI) is an emerging metabolic imaging modality that measures key metabolic phenotypes indicative of aggressive tumor phenotypes. Here we show that the pre-treatment tumor 13C-lactate to 13C-bicarbonate ratio – a marker of glycolysis and (indirectly) oxidative phosphorylation – measured via HP [1-13C]pyruvate MRI is a robust predictor of local recurrence (AUCROC=0.95, p=0.0008; AUCPRC=0.92) and can inform treatment decisions should the model predict a non-response to SRS.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords